1. Scrip
  2. >>Therapy Areas

Alexion Nabs Valuable Voucher On Strensiq Approval

 
• By Donna Young

Alexion Pharmaceuticals Inc. not only gained the FDA's approval on Oct. 23 for Strensiq (asfotase alfa) as a treatment for patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP), but the win also garnered the company a rare pediatric disease priority review voucher (PRV), potentially putting hundreds of millions of dollars in the firm's pocket.

Alexion Pharmaceuticals Inc. not only gained the FDA's approval on Oct. 23 for Strensiq (asfotase alfa) as a treatment for patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP), but the win also garnered the company a rare pediatric disease priority review voucher (PRV), potentially putting hundreds of millions of dollars in the firm's pocket.

Shares of Alexion rose $5.24 on Oct. 23, or 3.1%, before closing at $171.16, up $4.40, or 2.6%.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.